{
  "folder": "IC-325",
  "content": "{{knowledge objective\n|Identifiant=OIC-325-03-A\n|Item_parent=Identification and management of risks associated with medicines and biomaterials, iatrogenic risk, medicinal errors (see items 4 and 5)\n|Item_parent_short=Identification and management of risks associated with medicines and biomaterials, iatrogenic risk, medication errors (see items 4 and 5)\n|Rank=A\n|Title=Know the definition of inappropriate prescribing of medicines (PMI)\n|Description=None\n|Topic=Definition\n|Contributors=Marie Briet\n|Order=3}}\n\n==Definition==\nInappropriate prescribing refers to prescribing that creates more risks than benefits for the patient.\n\nInappropriateness may relate to :\n\n*Prescribing without a clinical indication, not complying with the marketing authorisation (MA) or the official recommendations of learned societies.\n*Failure to take into account the patient's characteristics when choosing the active ingredient, dose, galenic form or route of administration of the drug: age, weight, co-morbidities (chronic renal failure, hepatocellular insufficiency, etc.), pregnancy, breast-feeding, for example.\n*Failure to take account of potential drug interactions.",
  "question": {
    "question": "What is the primary characteristic of inappropriate prescribing of medicines (PMI)?",
    "option_a": "Prescribing that always follows the marketing authorisation (MA) without considering patient-specific factors",
    "option_b": "Prescribing that considers the patient's characteristics but ignores potential drug interactions",
    "option_c": "Prescribing that creates more risks than benefits for the patient",
    "option_d": "Prescribing that only considers the cost of the medication without evaluating its effectiveness",
    "correct_option": "C"
  }
}